Published in Amino Acids on December 23, 2014
Adipose Tissue Dysfunction and Altered Systemic Amino Acid Metabolism Are Associated with Non-Alcoholic Fatty Liver Disease. PLoS One (2015) 0.95
MicroRNA Expression Relating to Dietary-Induced Liver Steatosis and NASH. J Clin Med (2015) 0.81
Metabolic profiling of fatty liver in young and middle-aged adults - cross-sectional and prospective analyses of the Young Finns Study. Hepatology (2016) 0.80
Amino Acid Metabolism is Altered in Adolescents with Nonalcoholic Fatty Liver Disease-An Untargeted, High Resolution Metabolomics Study. J Pediatr (2016) 0.79
Transcriptional networks implicated in human nonalcoholic fatty liver disease. Mol Genet Genomics (2015) 0.77
Branched Chain Amino Acids Cause Liver Injury in Obese/Diabetic Mice by Promoting Adipocyte Lipolysis and Inhibiting Hepatic Autophagy. EBioMedicine (2016) 0.76
Unravelling the metabolic impact of SBS-associated microbial dysbiosis: Insights from the piglet short bowel syndrome model. Sci Rep (2017) 0.75
Metabolomic analysis shows differential hepatic effects of T2 and T3 in rats after short-term feeding with high fat diet. Sci Rep (2017) 0.75
Gene-set association tests for next-generation sequencing data. Bioinformatics (2016) 0.75
Metabolomic mechanisms of gypenoside against liver fibrosis in rats: An integrative analysis of proteomics and metabolomics data. PLoS One (2017) 0.75
A Branched-Chain Amino Acid-Related Metabolic Signature Characterizes Obese Adolescents with Non-Alcoholic Fatty Liver Disease. Nutrients (2017) 0.75
Metabolomic profiling distinction of human nonalcoholic fatty liver disease progression from a common rat model. Obesity (Silver Spring) (2017) 0.75
Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology (2005) 29.57
Steatohepatitis: a tale of two "hits"? Gastroenterology (1998) 13.21
A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metab (2009) 11.46
Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes (2001) 9.67
Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology (2010) 5.35
Epidemiology of non-alcoholic fatty liver disease. Dig Dis (2010) 3.44
Interplay between lipids and branched-chain amino acids in development of insulin resistance. Cell Metab (2012) 3.26
Pathophysiology of nonalcoholic steatohepatitis. J Clin Gastroenterol (2006) 2.59
Obesity-related elevations in plasma leucine are associated with alterations in enzymes involved in branched-chain amino acid metabolism. Am J Physiol Endocrinol Metab (2007) 2.46
Gene expression in human NAFLD. Am J Physiol Gastrointest Liver Physiol (2008) 2.33
Pathogenesis of steatohepatitis. Best Pract Res Clin Gastroenterol (2002) 2.16
Long term prognosis of fatty liver: risk of chronic liver disease and death. Gut (2004) 2.15
A molecular model of human branched-chain amino acid metabolism. Am J Clin Nutr (1998) 2.09
Emerging perspectives on essential amino acid metabolism in obesity and the insulin-resistant state. Adv Nutr (2011) 2.01
Plasma metabolomic profile in nonalcoholic fatty liver disease. Metabolism (2010) 1.77
Hepatic cytochrome P450 enzyme alterations in humans with progressive stages of nonalcoholic fatty liver disease. Drug Metab Dispos (2009) 1.67
Branched-chain amino acids prevent insulin-induced hepatic tumor cell proliferation by inducing apoptosis through mTORC1 and mTORC2-dependent mechanisms. J Cell Physiol (2012) 1.65
Acylcarnitines: reflecting or inflicting insulin resistance? Diabetes (2013) 1.54
The metabolic syndrome and cardiovascular disease. Ann Med (2006) 1.48
Epidemiology of the metabolic syndrome in the USA. J Dig Dis (2011) 1.39
Analysis of global and absorption, distribution, metabolism, and elimination gene expression in the progressive stages of human nonalcoholic fatty liver disease. Drug Metab Dispos (2011) 1.33
New diagnostic and treatment approaches in non-alcoholic fatty liver disease (NAFLD). Ann Med (2009) 1.32
Insulin resistance and the metabolism of branched-chain amino acids in humans. Amino Acids (2011) 1.25
Leucine and mTORC1: a complex relationship. Am J Physiol Endocrinol Metab (2012) 1.24
Variations in ATP-binding cassette transporter regulation during the progression of human nonalcoholic fatty liver disease. Drug Metab Dispos (2011) 1.24
Branched-chain amino acid catabolism: unique segregation of pathway enzymes in organ systems and peripheral nerves. Am J Physiol Endocrinol Metab (2003) 1.21
Hepatic, cardiovascular, and endocrine outcomes of the histological subphenotypes of nonalcoholic fatty liver disease. Semin Liver Dis (2008) 1.20
Characterization of a branched-chain amino-acid transporter SBAT1 (SLC6A15) that is expressed in human brain. Biochem Biophys Res Commun (2005) 1.08
Drug metabolism alterations in nonalcoholic fatty liver disease. Drug Metab Rev (2011) 1.07
Leucine and protein metabolism in obese Zucker rats. PLoS One (2013) 1.07
Prevalence and risk factors of non-alcoholic fatty liver disease in the elderly: results from the Rotterdam study. J Hepatol (2012) 1.05
Altered UDP-glucuronosyltransferase and sulfotransferase expression and function during progressive stages of human nonalcoholic fatty liver disease. Drug Metab Dispos (2012) 1.05
Branched-chain amino acids in liver diseases. World J Gastroenterol (2013) 0.99
Housekeeping gene variability in the liver of alcoholic patients. Alcohol Clin Exp Res (2011) 0.97
Protein characterization of NA+-independent system L amino acid transporter 3 in mice: a potential role in supply of branched-chain amino acids under nutrient starvation. Am J Pathol (2007) 0.94
Oral branched-chain amino acid granules reduce the incidence of hepatocellular carcinoma and improve event-free survival in patients with liver cirrhosis. Dig Dis (2011) 0.92
T-type amino acid transporter TAT1 (Slc16a10) is essential for extracellular aromatic amino acid homeostasis control. J Physiol (2012) 0.90
The small SLC43 family: facilitator system l amino acid transporters and the orphan EEG1. Mol Aspects Med (2012) 0.90
Long-term branched-chain amino acid supplementation improves glucose tolerance in patients with nonalcoholic steatohepatitis-related cirrhosis. Intern Med (2012) 0.85
Branched-chain amino acid-enriched nutrients improve nutritional and metabolic abnormalities in the early post-transplant period after living donor liver transplantation. J Hepatobiliary Pancreat Sci (2012) 0.83
Expression of common housekeeping genes is affected by disease in human hepatitis C virus-infected liver. Liver Int (2010) 0.83
Effect of branched-chain amino acid-enriched nutritional supplementation on interferon therapy in Japanese patients with chronic hepatitis C virus infection: a retrospective study. Virol J (2012) 0.78
Expedient data mining for nontargeted high-resolution LC-MS profiles of biological samples. Bioanalysis (2013) 0.78
Promoting coherent minimum reporting guidelines for biological and biomedical investigations: the MIBBI project. Nat Biotechnol (2008) 12.96
Proposed minimum reporting standards for chemical analysis Chemical Analysis Working Group (CAWG) Metabolomics Standards Initiative (MSI). Metabolomics (2007) 6.93
Summary recommendations for standardization and reporting of metabolic analyses. Nat Biotechnol (2005) 2.90
Metabonomic identification of two distinct phenotypes in Sprague-Dawley (Crl:CD(SD)) rats. Toxicol Sci (2005) 2.66
Differential expression of mouse hepatic transporter genes in response to acetaminophen and carbon tetrachloride. Toxicol Sci (2004) 1.98
Influence of arsenate and arsenite on signal transduction pathways: an update. Arch Toxicol (2010) 1.76
Hepatic cytochrome P450 enzyme alterations in humans with progressive stages of nonalcoholic fatty liver disease. Drug Metab Dispos (2009) 1.67
Tissue distribution and hepatic and renal ontogeny of the multidrug resistance-associated protein (Mrp) family in mice. Drug Metab Dispos (2005) 1.61
Induction of Mrp3 and Mrp4 transporters during acetaminophen hepatotoxicity is dependent on Nrf2. Toxicol Appl Pharmacol (2007) 1.60
Signal transduction from N-cadherin increases Bcl-2. Regulation of the phosphatidylinositol 3-kinase/Akt pathway by homophilic adhesion and actin cytoskeletal organization. J Biol Chem (2002) 1.49
Diversity in antioxidant response enzymes in progressive stages of human nonalcoholic fatty liver disease. Drug Metab Dispos (2010) 1.48
Characterization of hepatocellular carcinoma related genes and metabolites in human nonalcoholic fatty liver disease. Dig Dis Sci (2013) 1.48
MAP3Ks as central regulators of cell fate during development. Dev Dyn (2008) 1.44
A framework for human relevance analysis of information on carcinogenic modes of action. Crit Rev Toxicol (2003) 1.36
Analysis of global and absorption, distribution, metabolism, and elimination gene expression in the progressive stages of human nonalcoholic fatty liver disease. Drug Metab Dispos (2011) 1.33
Induction of drug-metabolizing enzymes by garlic and allyl sulfide compounds via activation of constitutive androstane receptor and nuclear factor E2-related factor 2. Drug Metab Dispos (2007) 1.29
Efflux transporter expression and acetaminophen metabolite excretion are altered in rodent models of nonalcoholic fatty liver disease. Drug Metab Dispos (2007) 1.29
The p34cdc2-related cyclin-dependent kinase 11 interacts with the p47 subunit of eukaryotic initiation factor 3 during apoptosis. J Biol Chem (2002) 1.29
Epigenetic remodeling during arsenical-induced malignant transformation. Carcinogenesis (2008) 1.27
Variations in ATP-binding cassette transporter regulation during the progression of human nonalcoholic fatty liver disease. Drug Metab Dispos (2011) 1.24
Nuclear factor-E2-related factor 2 expression in liver is critical for induction of NAD(P)H:quinone oxidoreductase 1 during cholestasis. Cell Stress Chaperones (2006) 1.23
Ablation of MEKK4 kinase activity causes neurulation and skeletal patterning defects in the mouse embryo. Mol Cell Biol (2005) 1.21
Drug-metabolizing enzyme and transporter expression in a mouse model of diabetes and obesity. Mol Pharm (2008) 1.21
Cysteine S-glycosylation, a new post-translational modification found in glycopeptide bacteriocins. FEBS Lett (2011) 1.19
Experimental non-alcoholic fatty liver disease results in decreased hepatic uptake transporter expression and function in rats. Eur J Pharmacol (2009) 1.16
Gender-specific and developmental influences on the expression of rat organic anion transporters. J Pharmacol Exp Ther (2002) 1.15
Normalization strategies for metabonomic analysis of urine samples. J Chromatogr B Analyt Technol Biomed Life Sci (2009) 1.14
Metabolomics in toxicology: preclinical and clinical applications. Toxicol Sci (2010) 1.14
Constitutive expression of various xenobiotic and endobiotic transporter mRNAs in the choroid plexus of rats. Drug Metab Dispos (2003) 1.09
Next-generation sequencing reveals the impact of repetitive DNA across phylogenetically closely related genomes of Orobanchaceae. Mol Biol Evol (2012) 1.08
The Nrf2 activator oltipraz also activates the constitutive androstane receptor. Drug Metab Dispos (2008) 1.08
Decreased hepatotoxic bile acid composition and altered synthesis in progressive human nonalcoholic fatty liver disease. Toxicol Appl Pharmacol (2013) 1.08
Drug metabolism alterations in nonalcoholic fatty liver disease. Drug Metab Rev (2011) 1.07
Induction of hepatobiliary efflux transporters in acetaminophen-induced acute liver failure cases. Drug Metab Dispos (2007) 1.06
Altered UDP-glucuronosyltransferase and sulfotransferase expression and function during progressive stages of human nonalcoholic fatty liver disease. Drug Metab Dispos (2012) 1.05
The death domain kinase RIP1 is essential for tumor necrosis factor alpha signaling to p38 mitogen-activated protein kinase. Mol Cell Biol (2003) 1.05
Immortalization of normal human mammary epithelial cells in two steps by direct targeting of senescence barriers does not require gross genomic alterations. Cell Cycle (2014) 1.05
Hepatic Mrp4 induction following acetaminophen exposure is dependent on Kupffer cell function. Am J Physiol Gastrointest Liver Physiol (2008) 1.04
Regulation of transporter expression in mouse liver, kidney, and intestine during extrahepatic cholestasis. Biochim Biophys Acta (2006) 1.04
Modeling human nonalcoholic steatohepatitis-associated changes in drug transporter expression using experimental rodent models. Drug Metab Dispos (2014) 1.04
Intestinal absorption of cadmium is associated with divalent metal transporter 1 in rats. Toxicol Sci (2002) 1.03
Dead or alive? Autofluorescence distinguishes heat-fixed from viable cells. Int J Hyperthermia (2009) 1.03
Phosphorylation of serine 526 is required for MEKK3 activity, and association with 14-3-3 blocks dephosphorylation. J Biol Chem (2006) 1.02
Tissue distribution, ontogeny and induction of the transporters Multidrug and toxin extrusion (MATE) 1 and MATE2 mRNA expression levels in mice. Life Sci (2008) 1.02
TGFβ2-mediated production of hyaluronan is important for the induction of epicardial cell differentiation and invasion. Exp Cell Res (2010) 1.02
Xenobiotic and endobiotic transporter mRNA expression in the blood-testis barrier. Drug Metab Dispos (2004) 1.02
Molecular mechanism of altered ezetimibe disposition in nonalcoholic steatohepatitis. Drug Metab Dispos (2011) 1.01
Dysfunction of organic anion transporting polypeptide 1a1 alters intestinal bacteria and bile acid metabolism in mice. PLoS One (2012) 1.00
Genes of the antioxidant response undergo upregulation in a rodent model of nonalcoholic steatohepatitis. J Biochem Mol Toxicol (2007) 0.98
Structure and dynamics of dark-state bovine rhodopsin revealed by chemical cross-linking and high-resolution mass spectrometry. Protein Sci (2006) 0.98
The adaptive endoplasmic reticulum stress response to lipotoxicity in progressive human nonalcoholic fatty liver disease. Toxicol Sci (2013) 0.98
Metabonomics in pharmaceutical discovery and development. J Proteome Res (2007) 0.98
Drug metabolizing enzyme induction pathways in experimental non-alcoholic steatohepatitis. Arch Toxicol (2008) 0.97
Quantitative evaluation of sebum lipid components with nuclear magnetic resonance. J Lipid Res (2007) 0.97
Contemporary issues in toxicology the role of metabonomics in toxicology and its evaluation by the COMET project. Toxicol Appl Pharmacol (2003) 0.97
Metabonomic evaluation of Schaedler altered microflora rats. Chem Res Toxicol (2007) 0.96
p53 induces distinct epigenetic states at its direct target promoters. BMC Genomics (2008) 0.96
Evidence for the involvement of xenobiotic-responsive nuclear receptors in transcriptional effects upon perfluoroalkyl acid exposure in diverse species. Reprod Toxicol (2009) 0.96
Diploidization and genome size change in allopolyploids is associated with differential dynamics of low- and high-copy sequences. Plant J (2013) 0.96
Tissue expression, ontogeny, and inducibility of rat organic anion transporting polypeptide 4. J Pharmacol Exp Ther (2002) 0.95
NMR-based metabolomics of mammalian cell and tissue cultures. J Biomol NMR (2011) 0.95
Arsenicals produce stable progressive changes in DNA methylation patterns that are linked to malignant transformation of immortalized urothelial cells. Toxicol Appl Pharmacol (2009) 0.94
Tissue distribution and chemical induction of multiple drug resistance genes in rats. Drug Metab Dispos (2002) 0.94
Characterization of organic anion-transporting polypeptide (Oatp) 1a1 and 1a4 null mice reveals altered transport function and urinary metabolomic profiles. Toxicol Sci (2011) 0.94
MEKK3 initiates transforming growth factor beta 2-dependent epithelial-to-mesenchymal transition during endocardial cushion morphogenesis. Circ Res (2008) 0.93
Advances in mass spectrometry applied to pharmaceutical metabolomics. Anal Bioanal Chem (2010) 0.93
Forum series: research strategies for safety evaluation of nanomaterials. Toxicol Sci (2005) 0.93
Arsenic-induced decreases in the vascular matrix. Toxicol Pathol (2008) 0.92
The cyclin-dependent kinase 11(p46) isoform interacts with RanBPM. Biochem Biophys Res Commun (2003) 0.92
Constitutive androstane receptor-mediated changes in bile acid composition contributes to hepatoprotection from lithocholic acid-induced liver injury in mice. Drug Metab Dispos (2009) 0.92
Thermal contribution of compact bone to intervening tissue-like media exposed to planar ultrasound. Phys Med Biol (2004) 0.92
A retrospective analysis of toxicogenomics in the safety assessment of drug candidates. Toxicol Pathol (2007) 0.92
p38 mitogen-activated protein kinase-dependent tumor necrosis factor-alpha-converting enzyme is important for liver injury in hepatotoxic interaction between lipopolysaccharide and ranitidine. J Pharmacol Exp Ther (2008) 0.92
Differential regulation of hepatic transporters in the absence of tumor necrosis factor-alpha, interleukin-1beta, interleukin-6, and nuclear factor-kappaB in two models of cholestasis. Drug Metab Dispos (2006) 0.91
Comparison of TNFα to lipopolysaccharide as an inflammagen to characterize the idiosyncratic hepatotoxicity potential of drugs: Trovafloxacin as an example. Int J Mol Sci (2010) 0.91
First transgenic rat model developing progressive cortical neurofibrillary tangles. Neurobiol Aging (2010) 0.91
Increased hexokinase II expression in the renal glomerulus of mice in response to arsenic. Toxicol Appl Pharmacol (2007) 0.91
Liver disease with altered bile acid transport in Niemann-Pick C mice on a high-fat, 1% cholesterol diet. Am J Physiol Gastrointest Liver Physiol (2005) 0.90
A proteomic study of resistance to deoxycholate-induced apoptosis. Carcinogenesis (2004) 0.90
Sex differences in the mRNA, protein, and functional expression of organic anion transporter (Oat) 1, Oat3, and organic cation transporter (Oct) 2 in rabbit renal proximal tubules. J Pharmacol Exp Ther (2005) 0.90
Immunohistochemical analysis of Clara cell secretory protein expression in a transgenic model of mouse lung carcinogenesis. Toxicology (2003) 0.90
Renal xenobiotic transporters are differentially expressed in mice following cisplatin treatment. Toxicology (2008) 0.90
Bile acid and sterol metabolism with combined HMG-CoA reductase and PCSK9 suppression. J Lipid Res (2013) 0.90